A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies

BACKGROUND: The combination of everolimus and the imidazoquinoline derivative, BEZ235 (dactolisib), a dual PI3K/mTOR inhibitor, demonstrated synergy in a preclinical model. OBJECTIVE: To establish clinical feasibility, a phase Ib dose-escalation trial investigating safety and pharmacokinetics of thi...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Target Oncol
Hlavní autoři: Wise-Draper, Trisha M., Moorthy, Ganesh, Salkeni, Mohamad A., Karim, Nagla Abdel, Thomas, Hala Elnakat, Mercer, Carol A., Beg, M. Shalaan, O’Gara, Sue, Olowokure, Olugbenga, Fathallah, Hassana, Kozma, Sara C., Thomas, George, Rixe, Olivier, Desai, Pankaj, Morris, John C.
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer International Publishing 2017
Témata:
Original Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5447332/
https://ncbi.nlm.nih.gov/pubmed/28357727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-017-0482-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky